PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic

Michael J Ryan1, Sean P Didion, Satya Mathur

  • 1Ph.D. Professor, Department of Internal Medicine, 3181 MERF, University of Iowa, Department of Internal Medicine Iowa City, IA 52242, USA. Curt-Sigmund@uiowa.edu

Insights

Rosiglitazone, a PPARgamma agonist, improved blood pressure and vascular function in hypertensive mice. This suggests direct vascular effects, potentially independent of PPARgamma, contribute to its cardiovascular benefits.

Area of Science:

  • Cardiovascular Pharmacology
  • Endocrinology
  • Molecular Biology

Background:

  • The cardiovascular benefits of rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, are not fully understood.
  • Hypertension is a significant risk factor for cardiovascular disease, and novel therapeutic mechanisms are needed.

Purpose of the Study:

  • To investigate the effects of rosiglitazone on blood pressure and vascular function in a transgenic mouse model of hypertension (R(+)A(+)).
  • To explore potential PPARgamma-dependent and independent mechanisms underlying rosiglitazone's vascular effects.

Main Methods:

  • Administration of oral rosiglitazone (25 mg/kg/day for 21 days) to R(+)A(+) mice and control littermates (RA(-)).
  • Measurement of systolic and mean blood pressure using tail-cuff and carotid artery catheterization.
  • Assessment of carotid artery relaxation responses to acetylcholine, nitric oxide, papaverine, and rosiglitazone.
  • Analysis of gene and protein expression for endothelial nitric oxide synthase (eNOS), angiotensin 1 receptors, preproendothelin-1, and soluble guanylyl cyclase.

Main Results:

  • Rosiglitazone significantly decreased systolic and mean blood pressure in R(+)A(+) mice.
  • Vascular relaxation to acetylcholine and nitric oxide was impaired in R(+)A(+) mice but improved after rosiglitazone treatment.
  • Rosiglitazone did not alter the expression of key genes or protein levels involved in the renin-angiotensin system or nitric oxide synthesis.
  • Carotid arteries exhibited concentration-dependent relaxation to rosiglitazone, independent of nitric oxide synthase or PPARgamma inhibition.

Conclusions:

  • Rosiglitazone improves blood pressure and vascular function in a model of hypertension.
  • These improvements may involve direct vascular effects of rosiglitazone, potentially independent of PPARgamma activation.
  • Further research is warranted to elucidate the precise mechanisms of rosiglitazone's cardiovascular actions.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...